ClinicalTrials.gg
CompletedNCT00735787Updated Nov 1, 2010Results posted

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

A Phase 4 interventional study of Placebo and Adalimumab in Psoriasis, sponsored by Abbott. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-01.

Sponsored by Abbott · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
34th of 48
81 · median 148
Started
2008
with 1 other
Phase 4
11 of 48
2 open now
Registered
11th of 48
by date
Lead sponsor
11 of 48
Abbott

Among the 48 studies testing adalimumab in Psoriasis, this one is the 34th largest by enrollment, is one of 2 that started in 2008, is one of 11 in phase 4, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult with Diagnosis of chronic plaque psoriasis of the Hands and Feet for at least 6 months, with a PGA >/=3 and candidates for systemic therapy;
  • Patients in good general health
  • Able to self-administer injections
  • Negative chest x-ray (CXR) and purified protein derivative (PPD) test, unless willing to start anti-tuberculosis (TB) prophylaxis

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with HUMIRA®
  • Required mediation stability or washouts for: systemic (28 days), other agent, other systemic therapies for psoriasis, ultraviolet B (UVB), psoralen with UVA (PUVA)
  • Other active skin diseases or skin infections
  • Diagnosis of palmoplantar pustulosis; erythrodermic psoriasis, pustular psoriasis, medication-induced or exacerbated psoriasis or new onset of guttate psoriasis
  • Evidence of dysplasia or history of (Other than a successfully treated non- cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix);
  • History of listeriosis, histoplasmosis, chronic or active infection, (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB);
  • History of moderate to severe congestive heart failure,
  • Recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk;
  • History of central nervous system (CNS) demyelinating disease or neurologic symptoms suggestive of CNS demyelinating disease;
  • History of drug or alcohol abuse in the last 12 months;
  • Infection(s) requiring treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to Baseline or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to Baseline;
  • Known to the of HUMIRA® as stated in the label;
  • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study.
  • Prior exposure to Tysabri® (natalizumab)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Placebo comparator
    Placebo/Adalimumab

    Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15. In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.

    Biological: Placebo · Biological: Adalimumab

  • Active comparator
    Adalimumab

    80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.

    Biological: Adalimumab

Interventions

  • BiologicalPlacebo

    Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.

  • BiologicalAdalimumab

    Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16

    Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling) at Week 16. The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

    Time frame: Week 16

Secondary outcomes

  1. Mean Change From Baseline in Erythema, Scaling, Induration, and Fissuring (ESIF)

    Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the two soles and two palms, for a total range from 0 (no disease) to 48 points (most severe condition). A decrease from Baseline in ESIF indicates improvement.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28

  2. Mean Change From Baseline in ESIF for Palms

    Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the palms of the hands, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the palms. A decrease from Baseline in ESIF indicates improvement.

    Time frame: Baseline and Weeks 2, 4, 12, 16, 20, 24, and 28

  3. Mean Change From Baseline in ESIF for Soles

    Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the soles of the feet, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the soles. A decrease from Baseline in ESIF indicates improvement.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28

  4. Number of Subjects With Moderate Improvement in ESIF From Baseline

    Number of subjects that achieved \> 50% reduction from Baseline in ESIF.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28

  5. Number of Subjects With Marked Improvement in ESIF From Baseline

    Number of subjects that achieved \> 75% reduction from Baseline in ESIF

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28

  6. Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

    For subjects with psoriasis nail involvement at Baseline, the target fingernail (most severely involved fingernail at Baseline) was assessed for NAPSI throughout the study. NAPSI ranges from 0 (no nail psoriasis) to 8 (most severe nail psoriasis).

    Time frame: Baseline and Weeks 8, 16, and 28

  7. Number of Subjects With Physicians Global Assessment of Psoriasis (PGA) of Clear, Almost Clear, or Mild

    Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis), almost clear (representing just perceptible erythema and scaling), or mild (representing light pink erythema with minimal scaling and with or without pustules). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and 28

  8. Number of Subjects With PGA of Clear or Almost Clear

    Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 20, 24, and 28

  9. Number of Subjects With PGA of Clear

    Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and 28

  10. Number of Subjects With Psoriasis Area and Severity Index (PASI) 50

    Number of subjects who achieved 50% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

    Time frame: Baseline and Weeks 16 and 28

  11. Number of Subjects With PASI 75

    Number of subjects who achieved 75% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

    Time frame: Baseline and Weeks 16 and 28

  12. Number of Subjects With PASI 90

    Number of subjects who achieved 90% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

    Time frame: Baseline and Weeks 16 and 28

  13. Number of Subjects With PASI 100

    Number of subjects who achieved 100% improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

    Time frame: Baseline and Weeks 16 and 28

  14. Mean Change From Baseline in Dermatology Life Quality Index (DLQI)

    The DLQI consists of 10 questions and is scored from 0 (total lack of impairment) to 30 (life is very much impaired). A decrease in DLQI indicates improvement.

    Time frame: Baseline and Weeks 2, 8, 16, and 28

  15. Number of Subjects Achieving a DLQI of 0

    Number of subjects achieving a DLQI score of 0, indicating total lack of impairment. The DLQI consists of 10 questions and is scored from 0 to 30 (life is very much impaired). A decrease in DLQI indicates improvement.

    Time frame: Baseline and Weeks 2, 8, 16, and 28

  16. Mean Change From Baseline in Visual Analog Scale (VAS) for Psoriasis and Psoriatic Arthritis Pain

    On one single VAS, subjects assessed their pain due to psoriasis (and psoriatic arthritis, if applicable). Mean change in psoriasis and psoriatic arthritis pain from Baseline as measured by a VAS from 0 (no pain) to 100 (pain as bad as it could be).

    Time frame: Baseline and Weeks 16 and 28

  17. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO)

    WPAI:PSO assesses the effect on the subject's ability to work and perform regular activities in 4 areas: % work time (in hours) missed due to psoriasis, % impairment while working (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), % overall work impairment (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), and % activity impairment (on a scale from 0 \[psoriasis having no effect on daily activities\] to 10 \[psoriasis completely prevented subject from doing daily activities\]).

    Time frame: Baseline and Weeks 8, 16, and 28

  18. Mean Change From Baseline in Patient Health Questionnaire (PHQ-9)

    The PHQ-9 consists of 9 questions that assess how often over the past 2 weeks subjects had signs or symptoms of depression (0=not at all, 1=several days, 2=more than half days, and 3=nearly every day). The PHQ-9 is the sum of the scores from the 9 questions for a total range from 0 (not depressed at all) to 27 (depressed nearly every day).

    Time frame: Baseline and Weeks 2, 8, 16, and 28

  19. Number of Subjects With Difficulties According to PHQ-9

    Based on the 9 questions of the PHQ-9, if subjects indicated any problems (PHQ-9 score \> 0), the difficulty to do work, take care of things at home, and get along with people (question 10 of the PHQ) were assessed (not difficult at all, somewhat difficult, very difficult, and extremely difficult).

    Time frame: Baseline and Weeks 2, 8, 16, and 28

07

Results

Posted Nov 1, 2010
Limitations and caveats
Based on one investigator's non-compliance with the protocol at one site, ITT analyses were conducted in a smaller number of subjects that excluded all 9 subjects from this one site.

Participant flow

Period 1
Participant flow — Period 1
MilestonePlacebo/AdalimumabAdalimumab
Started2349
Completed1741
Not completed68
Period 2
Participant flow — Period 2
MilestonePlacebo/AdalimumabAdalimumab
Started1841
Completed1340
Not completed51

Outcome measures

PrimaryNumber of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16

Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling) at Week 16. The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

Time frame:
Week 16
Reported as:
Number · subjects
Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16
subjectsPlacebo/AdalimumabAdalimumab
Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16115
Statistical analysis
  • Placebo/Adalimumab vs Adalimumab · Fisher Exact · p = 0.014
SecondaryMean Change From Baseline in Erythema, Scaling, Induration, and Fissuring (ESIF)

Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the two soles and two palms, for a total range from 0 (no disease) to 48 points (most severe condition). A decrease from Baseline in ESIF indicates improvement.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in Erythema, Scaling, Induration, and Fissuring (ESIF)
units on a scalePlacebo/AdalimumabAdalimumab
Week 2-2.35 ± 4.074-6.24 ± 7.685
Week 4-1.91 ± 7.019-7.73 ± 9.064
Week 8-3.04 ± 7.327-9.33 ± 9.335
Week 12-5.30 ± 6.825-10.80 ± 11.175
Week 16-5.04 ± 6.568-10.92 ± 12.460
Week 20 (open-label)-6.43 ± 8.805-11.69 ± 11.353
Week 24 (open-label)-5.83 ± 9.267-11.51 ± 11.502
Week 28 (open-label)-5.83 ± 8.574-11.96 ± 10.261
SecondaryMean Change From Baseline in ESIF for Palms

Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the palms of the hands, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the palms. A decrease from Baseline in ESIF indicates improvement.

Time frame:
Baseline and Weeks 2, 4, 12, 16, 20, 24, and 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in ESIF for Palms
units on a scalePlacebo/AdalimumabAdalimumab
Week 2-1.78 ± 3.464-3.33 ± 4.095
Week 4-1.57 ± 4.326-4.33 ± 4.543
Week 8-2.09 ± 4.889-5.35 ± 4.829
Week 12-3.39 ± 4.639-5.53 ± 5.934
Week 16-2.65 ± 4.914-5.80 ± 6.285
Week 20 (open-label)-3.87 ± 5.810-6.16 ± 5.669
Week 24 (open-label)-3.74 ± 5.387-6.08 ± 5.947
Week 28 (open-label)-3.52 ± 4.870-6.59 ± 5.244
SecondaryMean Change From Baseline in ESIF for Soles

Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the soles of the feet, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the soles. A decrease from Baseline in ESIF indicates improvement.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in ESIF for Soles
units on a scalePlacebo/AdalimumabAdalimumab
Week 2-0.57 ± 1.619-2.92 ± 4.650
Week 4-0.35 ± 3.915-3.39 ± 5.553
Week 8-0.96 ± 4.017-4.04 ± 5.972
Week 12-1.91 ± 3.965-5.35 ± 6.515
Week 16-2.39 ± 4.620-5.18 ± 7.132
Week 20 (open-label)-2.57 ± 5.358-5.47 ± 6.959
Week 24 (open-label)-2.09 ± 5.608-5.37 ± 7.082
Week 28 (open-label)-2.30 ± 5.431-5.31 ± 6.378
SecondaryNumber of Subjects With Moderate Improvement in ESIF From Baseline

Number of subjects that achieved \> 50% reduction from Baseline in ESIF.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Reported as:
Number · subjects
Number of Subjects With Moderate Improvement in ESIF From Baseline
subjectsPlacebo/AdalimumabAdalimumab
Week 218
Week 4210
Week 8317
Week 12620
Week 16421
Week 20 (open-label)619
Week 24 (open-label)621
Week 28 (open-label)319
SecondaryNumber of Subjects With Marked Improvement in ESIF From Baseline

Number of subjects that achieved \> 75% reduction from Baseline in ESIF

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Reported as:
Number · subjects
Number of Subjects With Marked Improvement in ESIF From Baseline
subjectsPlacebo/AdalimumabAdalimumab
Week 203
Week 405
Week 807
Week 12011
Week 16114
Week 20 (open-label)513
Week 24 (open-label)412
Week 28 (open-label)211
SecondaryMean Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

For subjects with psoriasis nail involvement at Baseline, the target fingernail (most severely involved fingernail at Baseline) was assessed for NAPSI throughout the study. NAPSI ranges from 0 (no nail psoriasis) to 8 (most severe nail psoriasis).

Time frame:
Baseline and Weeks 8, 16, and 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
units on a scalePlacebo/AdalimumabAdalimumab
Week 8-0.63 ± 1.061-0.88 ± 1.211
Week 16-0.13 ± 1.246-1.67 ± 1.593
Week 28 (open-label)-1.00 ± 1.852-2.00 ± 2.177
SecondaryNumber of Subjects With Physicians Global Assessment of Psoriasis (PGA) of Clear, Almost Clear, or Mild

Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis), almost clear (representing just perceptible erythema and scaling), or mild (representing light pink erythema with minimal scaling and with or without pustules). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and 28
Reported as:
Number · subjects
Number of Subjects With Physicians Global Assessment of Psoriasis (PGA) of Clear, Almost Clear, or Mild
subjectsPlacebo/AdalimumabAdalimumab
Week 2215
Week 4321
Week 8621
Week 12824
Week 16625
Week 20 (open-label)823
Week 24 (open-label)720
Week 28 (open-label)423
SecondaryNumber of Subjects With PGA of Clear or Almost Clear

Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 20, 24, and 28
Reported as:
Number · subjects
Number of Subjects With PGA of Clear or Almost Clear
subjectsPlacebo/AdalimumabAdalimumab
Week 214
Week 4110
Week 8212
Week 12314
Week 20 (open-label)511
Week 24 (open-label)512
Week 28 (open-label)212
SecondaryNumber of Subjects With PGA of Clear

Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and 28
Reported as:
Number · subjects
Number of Subjects With PGA of Clear
subjectsPlacebo/AdalimumabAdalimumab
Week 201
Week 402
Week 803
Week 1206
Week 1616
Week 20 (open-label)28
Week 24 (open-label)37
Week 28 (open-label)27
SecondaryNumber of Subjects With Psoriasis Area and Severity Index (PASI) 50

Number of subjects who achieved 50% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

Time frame:
Baseline and Weeks 16 and 28
Reported as:
Number · subjects
Number of Subjects With Psoriasis Area and Severity Index (PASI) 50
subjectsPlacebo/AdalimumabAdalimumab
Week 16521
Week 28 (open-label)821
SecondaryNumber of Subjects With PASI 75

Number of subjects who achieved 75% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

Time frame:
Baseline and Weeks 16 and 28
Reported as:
Number · subjects
Number of Subjects With PASI 75
subjectsPlacebo/AdalimumabAdalimumab
Week 16215
Week 28 (open-label)411
SecondaryNumber of Subjects With PASI 90

Number of subjects who achieved 90% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

Time frame:
Baseline and Weeks 16 and 28
Reported as:
Number · subjects
Number of Subjects With PASI 90
subjectsPlacebo/AdalimumabAdalimumab
Week 16010
Week 28 (open-label)410
SecondaryNumber of Subjects With PASI 100

Number of subjects who achieved 100% improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).

Time frame:
Baseline and Weeks 16 and 28
Reported as:
Number · subjects
Number of Subjects With PASI 100
subjectsPlacebo/AdalimumabAdalimumab
Week 1607
Week 28 (open-label)18
SecondaryMean Change From Baseline in Dermatology Life Quality Index (DLQI)

The DLQI consists of 10 questions and is scored from 0 (total lack of impairment) to 30 (life is very much impaired). A decrease in DLQI indicates improvement.

Time frame:
Baseline and Weeks 2, 8, 16, and 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in Dermatology Life Quality Index (DLQI)
units on a scalePlacebo/AdalimumabAdalimumab
Week 2-3.43 ± 3.435-4.35 ± 4.741
Week 8-3.09 ± 5.008-4.08 ± 5.541
Week 16-4.22 ± 4.936-4.78 ± 7.269
Week 28 (open-label)-4.74 ± 4.731-5.18 ± 7.499
SecondaryNumber of Subjects Achieving a DLQI of 0

Number of subjects achieving a DLQI score of 0, indicating total lack of impairment. The DLQI consists of 10 questions and is scored from 0 to 30 (life is very much impaired). A decrease in DLQI indicates improvement.

Time frame:
Baseline and Weeks 2, 8, 16, and 28
Reported as:
Number · subjects
Number of Subjects Achieving a DLQI of 0
subjectsPlacebo/AdalimumabAdalimumab
Week 213
Week 813
Week 1607
Week 28 (open-label)16
SecondaryMean Change From Baseline in Visual Analog Scale (VAS) for Psoriasis and Psoriatic Arthritis Pain

On one single VAS, subjects assessed their pain due to psoriasis (and psoriatic arthritis, if applicable). Mean change in psoriasis and psoriatic arthritis pain from Baseline as measured by a VAS from 0 (no pain) to 100 (pain as bad as it could be).

Time frame:
Baseline and Weeks 16 and 28
Reported as:
Mean · mm on scale
Mean Change From Baseline in Visual Analog Scale (VAS) for Psoriasis and Psoriatic Arthritis Pain
mm on scalePlacebo/AdalimumabAdalimumab
Week 16-12.45 ± 28.637-17.49 ± 34.451
Week 28 (open-label)-16.25 ± 24.950-16.59 ± 34.430
SecondaryMean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO)

WPAI:PSO assesses the effect on the subject's ability to work and perform regular activities in 4 areas: % work time (in hours) missed due to psoriasis, % impairment while working (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), % overall work impairment (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), and % activity impairment (on a scale from 0 \[psoriasis having no effect on daily activities\] to 10 \[psoriasis completely prevented subject from doing daily activities\]).

Time frame:
Baseline and Weeks 8, 16, and 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO)
units on a scalePlacebo/AdalimumabAdalimumab
% Work Time Missed due to Psoriasis Week 86.32 ± 24.9534.70 ± 12.778
% Work Time Missed due to Psoriasis Week 167.72 ± 33.2995.34 ± 20.250
% Work Time Missed due to Psoriasis Week 28 (OL)2.60 ± 26.6283.16 ± 18.198
% Impairment While Working Week 80.71 ± 29.733-8.21 ± 27.087
% Impairment While Working Week 16-4.67 ± 20.656-5.94 ± 27.103
% Impairment While Working Week 28 (OL)-5.33 ± 20.999-8.44 ± 31.429
% Overall Work Impairment Week 8-0.48 ± 29.988-8.97 ± 27.355
% Overall Work Impairment Week 16-5.45 ± 22.432-7.19 ± 26.556
% Overall Work Impairment Week 28 (OL)-5.79 ± 20.996-9.88 ± 31.045
% Activity Impairment Week 8-9.09 ± 32.500-11.02 ± 23.562
% Activity Impairment Week 16-9.09 ± 22.234-13.88 ± 27.600
% Activity Impairment Week 28 (OL)-15.91 ± 27.196-14.69 ± 32.539
SecondaryMean Change From Baseline in Patient Health Questionnaire (PHQ-9)

The PHQ-9 consists of 9 questions that assess how often over the past 2 weeks subjects had signs or symptoms of depression (0=not at all, 1=several days, 2=more than half days, and 3=nearly every day). The PHQ-9 is the sum of the scores from the 9 questions for a total range from 0 (not depressed at all) to 27 (depressed nearly every day).

Time frame:
Baseline and Weeks 2, 8, 16, and 28
Reported as:
Mean · units on a scale
Mean Change From Baseline in Patient Health Questionnaire (PHQ-9)
units on a scalePlacebo/AdalimumabAdalimumab
Week 2-2.85 ± 4.332-2.86 ± 4.449
Week 8-2.43 ± 4.057-1.80 ± 4.796
Week 16-2.64 ± 6.637-2.14 ± 4.659
Week 28 (open-label)-3.32 ± 5.719-2.65 ± 5.031
SecondaryNumber of Subjects With Difficulties According to PHQ-9

Based on the 9 questions of the PHQ-9, if subjects indicated any problems (PHQ-9 score \> 0), the difficulty to do work, take care of things at home, and get along with people (question 10 of the PHQ) were assessed (not difficult at all, somewhat difficult, very difficult, and extremely difficult).

Time frame:
Baseline and Weeks 2, 8, 16, and 28
Reported as:
Number · subjects
Number of Subjects With Difficulties According to PHQ-9
subjectsPlacebo/AdalimumabAdalimumab
Not difficult at all - Baseline420
Somewhat difficult - Baseline919
Very difficult - Baseline35
Extremely difficult - Baseline75
Not difficult at all - Week 2521
Somewhat difficult - Week 2916
Very difficult - Week 223
Extremely difficult - Week 279
Not difficult at all - Week 8418
Somewhat difficult - Week 8815
Very difficult - Week 825
Extremely difficult - Week 8911
Not difficult at all - Week 16319
Somewhat difficult - Week 16810
Very difficult - Week 1621
Extremely difficult - Week 161019
Not difficult at all - Week 28 (OL)421
Somewhat difficult - Week 28 (OL)56
Very difficult - Week 28 (OL)21
Extremely difficult - Week 28 (OL)1221

Adverse events

Collected over All adverse events (AEs) from the time of study drug administration until 70 days following completion (Week 28) or discontinuation of study drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Adalimumab—1/23 (4.3%)15/23 (65.2%)
Adalimumab—2/49 (4.1%)30/49 (61.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo/AdalimumabAdalimumab
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/230/49
Breast massReproductive system and breast disorders1/230/49
Acute myocardial infarctionCardiac disorders0/231/49
Gastrointestinal haemorrhageGastrointestinal disorders0/231/49
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlacebo/AdalimumabAdalimumab
NasopharyngitisInfections and infestations3/2313/49
HeadacheNervous system disorders1/237/49
DiarrhoeaGastrointestinal disorders3/231/49
BronchitisInfections and infestations3/231/49
Gastrooesophageal reflux diseaseGastrointestinal disorders2/230/49
NauseaGastrointestinal disorders2/230/49
ToothacheGastrointestinal disorders2/230/49
Injection site reactionGeneral disorders2/232/49
Oedema peripheralGeneral disorders2/232/49
Urinary tract infectionInfections and infestations2/230/49

Baseline characteristics

Age Categorical
Age Categorical(subjects)Placebo/AdalimumabAdalimumabTotal
< 40 years11112
Between 40 and < 60 years142943
>= 60 years8917
Age Continuous
Age Continuous(years)Placebo/AdalimumabAdalimumabTotal
Mean54.8 ± 11.4049.0 ± 11.4150.9 ± 11.65
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/AdalimumabAdalimumabTotal
Female152843
Male82129
Region of Enrollment
Region of Enrollment(participants)Placebo/AdalimumabAdalimumabTotal
United States92029
Canada142943
08

Study locations

17 sites
  • Site Reference ID/Investigator# 10168
    Little Rock, Arkansas 72205, United States
  • Site Reference ID/Investigator# 10005
    Bakersfield, California 93309, United States
  • Site Reference ID/Investigator# 10003
    Macon, Georgia 31217, United States
  • Site Reference ID/Investigator# 10171
    St. Louis, Missouri 63117, United States
  • Site Reference ID/Investigator# 10164
    East Windsor, New Jersey 08520, United States
  • Site Reference ID/Investigator# 10173
    Dallas, Texas 75246-1613, United States
  • Site Reference ID/Investigator# 11302
    Houston, Texas 77030, United States
  • Site Reference ID/Investigator# 10166
    San Antonio, Texas 78258, United States
  • Site Reference ID/Investigator# 10180
    Edmonton, Alberta T5K 1X3, Canada
  • Site Reference ID/Investigator# 10169
    Vancouver, British Columbia V5Z 4E8, Canada
  • Site Reference ID/Investigator# 10170
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Site Reference ID/Investigator# 10179
    Hamilton, Ontario L8N 1V6, Canada
  • Site Reference ID/Investigator# 10004
    London, Ontario N5X 2P1, Canada
  • Site Reference ID/Investigator# 10177
    North Bay, Ontario P1B 3Z7, Canada
  • Site Reference ID/Investigator# 10175
    Waterloo, Ontario N2J 1C4, Canada
  • Site Reference ID/Investigator# 10165
    Montreal, Quebec H2K 4L5, Canada
  • Site Reference ID/Investigator# 10176
    Quebec, G1V 4X7, Canada
09

References and documents

Publications

  • Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20. PubMed 21173304 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2008
First posted
Aug 15, 2008
Start
Aug 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Nov 1, 2010
Last update
Nov 1, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00735787
Lead sponsor
Abbott
First posted
Aug 15, 2008
Start date
Aug 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Nov 1, 2010
Last update
Nov 1, 2010

Study contacts

Martin Okun, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion